If you or a loved one has taken Tysabri and stopped, you may still face a risk of progressive multifocal leukoencephalopathy (PML). This rare but serious brain infection can emerge months or even years after the last dose. Decades of pharmacovigilance and clinical research have established that PML risk does not disappear when treatment ends. This page explains the known timeline, symptoms to watch for, and why ongoing vigilance matters.
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its prescribing information includes a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning identifies three risk factors for PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors must be considered when initiating and continuing therapy. PML is a demyelinating disease of the central nervous system that presents with progressive neurological deficits. Clinical presentation can include cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis typically involves brain MRI showing white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The disease often leads to severe disability or death, as noted in the boxed warning. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri blocks the adhesion molecule VLA-4 on lymphocytes, preventing their migration across the blood-brain barrier. This reduces immune surveillance in the central nervous system, allowing latent JC virus to reactivate and cause lytic infection of oligodendrocytes. The resulting demyelination produces the characteristic PML lesions. FDA adverse event reports from the FAERS database list fatigue, multiple sclerosis relapse, headache, and gait disturbance among the most frequently reported events for Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is a known serious risk, the reporting system captures a wide range of adverse events that may overlap with underlying disease symptoms.
The adequacy of warnings regarding Tysabri and PML is a key consideration. The boxed warning clearly states the increased risk and identifies specific risk factors. The prescribing information mandates monitoring for new signs or symptoms suggestive of PML and immediate withholding of Tysabri at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH Prescribing Program restricts distribution and requires regular patient evaluations, including assessments three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals must report cases of PML, hospitalizations due to opportunistic infections, and deaths to Biogen. For patients affected by PML after Tysabri treatment, attorney-related considerations include the statute of limitations for filing claims in Texas. In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For product liability claims involving prescription drugs, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that the injury was caused by the drug. Given the latency between Tysabri exposure and PML diagnosis, the timeline between exposure and documented harm is critical. PML can develop months to years after starting Tysabri, and symptoms may be subtle initially. The boxed warning notes that risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This extended timeline can complicate statute of limitations calculations, as the injury may not be immediately apparent. Patients who develop PML after Tysabri treatment should seek legal counsel promptly to evaluate their specific circumstances. The adequacy of warnings provided by the manufacturer and healthcare providers may be relevant to potential claims. The boxed warning and prescribing information provide detailed risk information, but questions may arise about whether patients received and understood these warnings. The TOUCH program requires patient enrollment and regular reauthorization, which may document the informed consent process.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For product liability claims involving prescription drugs, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that the injury was caused by the drug. Given the latency between Tysabri exposure and PML diagnosis, it is crucial to seek legal counsel promptly.
The prescribing information identifies three risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors must be considered when initiating and continuing therapy.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.